182 related articles for article (PubMed ID: 21622724)
1. FGFR-4 Arg³⁸⁸ enhances prostate cancer progression via extracellular signal-related kinase and serum response factor signaling.
Yu W; Feng S; Dakhova O; Creighton CJ; Cai Y; Wang J; Li R; Frolov A; Ayala G; Ittmann M
Clin Cancer Res; 2011 Jul; 17(13):4355-66. PubMed ID: 21622724
[TBL] [Abstract][Full Text] [Related]
2. Targeting fibroblast growth factor receptor signaling inhibits prostate cancer progression.
Feng S; Shao L; Yu W; Gavine P; Ittmann M
Clin Cancer Res; 2012 Jul; 18(14):3880-8. PubMed ID: 22573348
[TBL] [Abstract][Full Text] [Related]
3. The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression.
Wang J; Stockton DW; Ittmann M
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6169-78. PubMed ID: 15448004
[TBL] [Abstract][Full Text] [Related]
4. Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression.
Wang J; Yu W; Cai Y; Ren C; Ittmann MM
Neoplasia; 2008 Aug; 10(8):847-56. PubMed ID: 18670643
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of the metastasis-associated gene Ehm2 in prostate cancer.
Wang J; Cai Y; Penland R; Chauhan S; Miesfeld RL; Ittmann M
Prostate; 2006 Nov; 66(15):1641-52. PubMed ID: 16927306
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
[TBL] [Abstract][Full Text] [Related]
7. Amplification of FRS2 and activation of FGFR/FRS2 signaling pathway in high-grade liposarcoma.
Zhang K; Chu K; Wu X; Gao H; Wang J; Yuan YC; Loera S; Ho K; Wang Y; Chow W; Un F; Chu P; Yen Y
Cancer Res; 2013 Feb; 73(4):1298-307. PubMed ID: 23393200
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
9. Regulation of metastasis of pediatric multiple myeloma by MMP13.
Wang X; Cao X
Tumour Biol; 2014 Sep; 35(9):8715-20. PubMed ID: 24870599
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
11. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion.
Xiao LJ; Lin P; Lin F; Liu X; Qin W; Zou HF; Guo L; Liu W; Wang SJ; Yu XG
Int J Oncol; 2012 May; 40(5):1714-24. PubMed ID: 22200661
[TBL] [Abstract][Full Text] [Related]
12. Conditional activation of fibroblast growth factor receptor (FGFR) 1, but not FGFR2, in prostate cancer cells leads to increased osteopontin induction, extracellular signal-regulated kinase activation, and in vivo proliferation.
Freeman KW; Gangula RD; Welm BE; Ozen M; Foster BA; Rosen JM; Ittmann M; Greenberg NM; Spencer DM
Cancer Res; 2003 Oct; 63(19):6237-43. PubMed ID: 14559809
[TBL] [Abstract][Full Text] [Related]
13. Ectopic fibroblast growth factor receptor 1 promotes inflammation by promoting nuclear factor-κB signaling in prostate cancer cells.
Wang C; Ke Y; Liu S; Pan S; Liu Z; Zhang H; Fan Z; Zhou C; Liu J; Wang F
J Biol Chem; 2018 Sep; 293(38):14839-14849. PubMed ID: 30093411
[TBL] [Abstract][Full Text] [Related]
14. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells.
Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV
Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196
[TBL] [Abstract][Full Text] [Related]
15. MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.
Mehta PB; Jenkins BL; McCarthy L; Thilak L; Robson CN; Neal DE; Leung HY
Oncogene; 2003 Mar; 22(9):1381-9. PubMed ID: 12618764
[TBL] [Abstract][Full Text] [Related]
16. ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.
Nakanishi Y; Mizuno H; Sase H; Fujii T; Sakata K; Akiyama N; Aoki Y; Aoki M; Ishii N
Mol Cancer Ther; 2015 Dec; 14(12):2831-9. PubMed ID: 26438159
[TBL] [Abstract][Full Text] [Related]
17. Role of GLI-1 in epidermal growth factor-induced invasiveness of ARCaPE prostate cancer cells.
Zhu G; Zhou J; Song W; Wu D; Dang Q; Zhang L; Li L; Wang X; He D
Oncol Rep; 2013 Aug; 30(2):904-10. PubMed ID: 23757299
[TBL] [Abstract][Full Text] [Related]
18. IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer.
Fujisawa T; Joshi BH; Puri RK
Int J Cancer; 2012 Jul; 131(2):344-56. PubMed ID: 21858811
[TBL] [Abstract][Full Text] [Related]
19. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract][Full Text] [Related]
20. Increased expression of matrix metalloproteinases mediates thromboxane A2-induced invasion in lung cancer cells.
Li X; Tai HH
Curr Cancer Drug Targets; 2012 Jul; 12(6):703-15. PubMed ID: 22515524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
